FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 911 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR DIY Mosquito Traps & Deterrents (That Really Work) June 23, 2021 Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... August 31, 2021 Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... December 17, 2020 Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes June 3, 2022 Load more HOT NEWS Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is...
